Table 3: Utilities and costs used in the model

Parameter used in model	Value	Low range of sensitivity analyses	High range of sensitivity analyses	Distribution used in probabilistic analysis	Reference nos.
Utilities
Utility of post-ACS state in absence of heart failure	0.91	0.56	1.00	Beta	24
Utility of post-ACS state in presence of heart failure	0.55	0	1.00	Beta	24
Utility decrement associated with ACS	0.18 for 1 mo	0.10	0.26	Beta	25
Utility decrement associated with major bleed	0.16 for 1 mo	0	0.57	Beta	26
Utility decrements of minor adverse effects	0.02	0	0.18	Beta	25, 26
Utility decrement associated with twice daily dosing for ticagrelor	0.0001	0	0.04	Beta	Assumption
Costs, $
Monthly cost of post-ACS state in presence of heart failure	361.25	220	503	Gamma	27
Monthly cost of post-ACS state in absence of heart failure	165.25	100	230	Gamma	27
Cost of ACS hospitalization	9 774	0	32 404	Gamma	28
Hospitalization cost of major bleed	10 805	0	38 255	Gamma	28
Physician billing during ACS hospitalization	1 461	1 417	1 505	Gamma	29, assumption
Physician billing during hospitalization for major bleed	588	560	616	Gamma	29, assumption
Monthly cost of clopidogrel	20.09	15	25	NA	30
Monthly cost of prasugrel	80.96	70	92	NA	30
Monthly cost of ticagrelor	90.10	79	101	NA	30

Note: ACS = acute coronary syndrome, NA = not available.